FDA Approves First Biosimilar to Neulasta to Decrease the Risk of Infection During Cancer Treatment

Jun 03

2018

The Food and Drug Administration approved Fulphila (pegfilgrastim-jmdb, Mylan GmbH) as a biosimilar to Neulasta (pegfilgrastim, Amgen, Inc.) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

Citations

APA

American Society of Hematology. (2018).
FDA Approves First Biosimilar to Neulasta to Decrease the Risk of Infection During Cancer Treatment.
Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-first-biosimilar-to-neulasta-to-decrease-the-risk-of-infection-during-cancer-treatment.

Chicago

American Society of Hematology.
"FDA Approves First Biosimilar to Neulasta to Decrease the Risk of Infection During Cancer Treatment." Hematology.org.
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-first-biosimilar-to-neulasta-to-decrease-the-risk-of-infection-during-cancer-treatment
(label-accessed December 12, 2024).

MLA

"American Society of Hematology."
FDA Approves First Biosimilar to Neulasta to Decrease the Risk of Infection During Cancer Treatment, 12 Dec. 2024 ,
https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2018/fda-approves-first-biosimilar-to-neulasta-to-decrease-the-risk-of-infection-during-cancer-treatment.

Citation Manager Formats

BibLaTeX
Bookends
EasyBib
EndNote
Mendeley
Papers
RIS
Ref Manager
RefWorks
Zotero

Related Content

Help ASH Build an Inclusive Hematology Community!

ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.

How Can You Help?

Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!

Update Access to Demographic Information Learn About Our Mission